^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GC502
i
Other names: GC502, CD19/CD7-Targeting CAR-T, TruUCAR-enabled CD19/CD7 dual-directed allogeneic CAR-T cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AstraZeneca
Drug class:
CD19-targeted CAR-T immunotherapy, CD7-targeted CAR-T immunotherapy
Related drugs:
over2years
EARLY RESULTS OF A SAFETY AND EFFICACY STUDY OF ALLOGENEIC TRUUCAR™ GC502 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) (EHA 2022)
CRS in all pts was manageable and resolved after treatment with Ruxolitinib, SOC and supportive care. Robust CAR-T cell expansion was observed in DL2 at 1.5x10 7 cells/kg in heavily pretreated r/r B-ALL patients, including those previously treated with CD19 or CD19-CD22 CAR-T therapies. The study is ongoing and continues accruing patients.
Clinical
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CD7 (CD7 Molecule)
|
Jakafi (ruxolitinib) • GC502
3years
Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies (ASH 2021)
It demonstrated robust anti-tumor efficacy and promising potentials to suppress HvG. This report presents an example that the dual CAR design of GC502 may serve as a novel “off-the-shelf” CAR-T technology.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CD7 (CD7 Molecule)
|
CD19 expression
|
GC027 • GC502
Share via
